These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 4089643)

  • 41. [Effect of nifedipine on the ventricular function and peripheral vascular system in normal subjects and in patients with coronary disease].
    Horta PE; de Carvalho VB; Arie S; Macruz R; Pileggi FJ; Décourt LV
    Arq Bras Cardiol; 1982 Jan; 38(1):25-8. PubMed ID: 7150050
    [No Abstract]   [Full Text] [Related]  

  • 42. Oxyfedrine and cardiac inotropism in coronary artery disease.
    Krishnaswami S; Sathyamurthy I; Mao R; Padmakumar P
    Indian Heart J; 1984; 36(3):161-5. PubMed ID: 6490047
    [No Abstract]   [Full Text] [Related]  

  • 43. [Comparative study of the acute hemodynamic effects of verapamil and nifedipine in patients with ischemic heart disease].
    Manfroi WC; Vieira SR; Ludwig RT; Goldim JR; Faraco EZ
    Arq Bras Cardiol; 1987 Feb; 48(2):123-8. PubMed ID: 3675228
    [No Abstract]   [Full Text] [Related]  

  • 44. [Polygraphic and electrocardiographic study of a new coronary therapeutic agent: dilazep].
    Parenti B; Selvaggi R
    Clin Ter; 1980 Jan; 92(2):155-63. PubMed ID: 7389275
    [No Abstract]   [Full Text] [Related]  

  • 45. Influence of severity of ventricular dysfunction on hemodynamic responses to intravenously administered verapamil in ischemic heart disease.
    Chew CY; Hecht HS; Collett JT; McAllister RG; Singh BN
    Am J Cardiol; 1981 Apr; 47(4):917-22. PubMed ID: 7211708
    [No Abstract]   [Full Text] [Related]  

  • 46. [Effect of intravenous propranolol on resting and post-exercise left ventricular contraction in patients with coronary disease].
    Markiewicz K; Gawor Z; Cholewa M
    Kardiol Pol; 1984; 27(10):817-27. PubMed ID: 6535029
    [No Abstract]   [Full Text] [Related]  

  • 47. [Indications for the use of phosphocreatine in cardiology].
    Pinelli G; Di Pasquale G; Alberici S; Manini G; Coluccini M
    Clin Ter; 1982 Feb; 100(3):261-79. PubMed ID: 7060343
    [No Abstract]   [Full Text] [Related]  

  • 48. [Non-invasive evaluation of left ventricular function in cardiopathic patients during short-term and long-term treatment with flurazepam].
    Bonaduce D; Spirito G; Romano M; Ferrara N; Petretta M; Rengo F; Condorelli M
    Minerva Cardioangiol; 1979 Dec; 27(12):793-800. PubMed ID: 550093
    [No Abstract]   [Full Text] [Related]  

  • 49. [The role of calcium antagonists in the treatment of arrhythmias in myocardial ischemia].
    Sannino A; Calabretta G; Raddi G; Santamaria G; Russo C
    Minerva Med; 1980 Mar; 71(8):597-8. PubMed ID: 7360390
    [No Abstract]   [Full Text] [Related]  

  • 50. [Effect of Sensit on central hemodynamics in patients with ischemic heart disease].
    Kliuka GR; Sinitsa KI; Okhon'ko VI; Sinitsa TN; Pilipchuk LR
    Vrach Delo; 1987 Nov; (11):19-20. PubMed ID: 3439113
    [No Abstract]   [Full Text] [Related]  

  • 51. [Use of verapamil in the treatment of ventricular extrasystole in chronic Chagas' heart disease].
    Vichi FL; Nobre F; Evora P; Ribeiro PJ; Papa MV
    Arq Bras Cardiol; 1977 Feb; 30 Suppl 1():101-6. PubMed ID: 407891
    [No Abstract]   [Full Text] [Related]  

  • 52. [Long-term administration of verapamil in coronary disease].
    Tkaczewski W; Goch JH; Bala T; Kuklewicz C
    Pol Tyg Lek; 1977 Oct; 32(44):1719-21. PubMed ID: 917918
    [No Abstract]   [Full Text] [Related]  

  • 53. [The role of the sympathomimetic activity of beta-adrenergic blockaders in the treatment of patients with chronic ischemic heart disease].
    Ol'binskaia LI; Bragina GI
    Ter Arkh; 1983; 55(9):35-40. PubMed ID: 6138864
    [No Abstract]   [Full Text] [Related]  

  • 54. [Ultrasonocardiographic evaluation of the nitroglycerin effect on left-ventricular size and myocardial contractility in coronary disease].
    Trojnar R; Rymar B; Dubejko J; Markiewicz M
    Pol Tyg Lek; 1980 Dec; 35(48):1853-5. PubMed ID: 6782557
    [No Abstract]   [Full Text] [Related]  

  • 55. [Hemodynamic action of curantil in ischemic heart disease].
    Zaslavskaia RM; Zolotaia RD
    Sov Med; 1981; (3):80-3. PubMed ID: 7244840
    [No Abstract]   [Full Text] [Related]  

  • 56. [Action of verapamil in coronariopathic patients. Evaluation using the ergometric test].
    Duarte GM; Ribeiro LG; Coelho W; Thevenard R; Souza PJ; Gonçalves MA; Carneiro RD; Luna RL
    Arq Bras Cardiol; 1976 Aug; 29(4):338-45. PubMed ID: 1008726
    [No Abstract]   [Full Text] [Related]  

  • 57. [Value of verapamil in long-term treatment of coronary disease, hypertension and functional disorders of the cardiovascular system].
    Tkaczewski W; Goch JH
    Wiad Lek; 1979 Oct; 32(19):1359-62. PubMed ID: 506277
    [No Abstract]   [Full Text] [Related]  

  • 58. [Verapamil in a single dose, evaluation by means of the ergometric test].
    Pereira MH; Brito FS; Pereira CB; Lion MF
    Arq Bras Cardiol; 1977 Feb; 30 Suppl 1():83-94. PubMed ID: 889475
    [No Abstract]   [Full Text] [Related]  

  • 59. Haemodynamic dose-response effects of i.v. verapamil in coronary artery disease.
    Silke B; Verma SP; Ahuja RC; Nelson GI; Hussain M; Taylor SH
    Herz; 1984 Dec; 9(6):353-61. PubMed ID: 6510876
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [The antiarrhythmic and coronary-dilating properties of verapamil in patients ith ischemic heart disease].
    Votcal BE; Lozinskij LG; Goldberg VA; Venediktova MG; Gribova OA
    Arzneimittelforschung; 1970 Sep; 20():Suppl 9a:1281+. PubMed ID: 5312386
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.